Spineway SA (ALSPW) AI Stock Analysis

• Market Cap: €5.46M
• Dividend Yield: N/A
• Average Volume (3M): 1.29M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.06
• Revenue Growth: -5.46%
• EPS Growth: 99.75%
• Country: FR
• Employees: 48
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.02
• Shares Outstanding: 35,544,390
• 10 Day Avg. Volume: 3,343,126
• 30 Day Avg. Volume: 1,288,542
• PEG Ratio: 0.06
• Price to Book (P/B): 0.94
• Price to Sales (P/S): 1.90
• P/FCF Ratio: -6.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.04
• Revenue Forecast (FY): €14.90M

• Rating: 48 Neutral
• Price Target: €0.18 ▼(-7.89% Downside)
• Action: Reiterated Date: 11/06/25
• Date: Action: Reiterated 11/06/25

The overall stock score is primarily influenced by financial performance challenges, including negative profitability and cash flow issues, which weigh heavily on the score. Technical analysis provides some positive momentum, but valuation concerns due to a negative P/E ratio and lack of dividends further impact the score negatively. The absence of earnings call and corporate events data means these factors do not contribute to the evaluation.

Positive Factors

Low Leverage / Conservative Balance Sheet

A debt-to-equity of 0.075 indicates conservative leverage and limited interest burden. This structural financial strength gives Spineway flexibility to fund R&D, commercial expansion or absorb reimbursement changes without major refinancing risk over the next several quarters.

Strong Revenue Growth

A nearly 70% year increase in revenue reflects strong product adoption and market penetration in spinal implants. Sustained top-line growth can deliver scale economies, support expanded clinical adoption and provide resources to address margins and commercial expansion over months.

Improving Gross Margin

An improved gross margin to 28.1% suggests better pricing, mix, or cost control at the product level. Structurally higher gross margins create room to absorb SG&A and R&D expenses and form a credible pathway toward sustainable operating profitability as sales scale.

Negative Factors

Persistent Net Losses

A deeply negative net margin erodes equity and limits reinvestable cash. Unless Spineway materially improves cost structure or pricing, ongoing losses will necessitate external funding, constrain long-term investment, and risk dilution or slowed commercial rollout over multiple quarters.

Weak Cash Generation

A 55% decline in free cash flow and negative operating cash conversion indicate structural liquidity pressure. Persistent weak cash generation forces reliance on financing for working capital and capex, increasing execution risk for commercialization and R&D over the medium term.

Negative Returns on Equity

A negative ROE signals the company is not generating returns from shareholders' capital. Persistent negative ROE implies inefficient capital allocation and undermines ability to attract non-dilutive financing, complicating plans to scale and reach profitability in coming quarters.

Spineway SA Business Overview & Revenue Model

Company Description

Spineway SA engages in the design, manufacture, and marketing of implants and surgical instruments for treating disorder of spinal column. The company offers ayers rock, an anterior cervical interbody fusion cage; blue mountain, an anterior cervical interbody fusion plate; mont blanc, a posterior thoracolumbar pedicle screws; mont blanc baby, a pediatric growing rod system; mont blanc 3d+, a coplanar alignment system; kili, an anterior lumbar interbody fusion cage; twin peaks plif bullet shaped posterior lumbar interbody fusion cages; twin peaks olif graft vascularization interbody fusion cages; twin peaks tlif transforaminal lumbar interbody fusion cages; and mont blanc mis, a mini-invasive thoracolumbar system. It also provides sonora, a biomaterial for bone regeneration. In addition, the company exports its products. Spineway SA was incorporated in 2005 and is headquartered in Ecully, France.

How the Company Makes Money

Spineway generates revenue primarily through the sale of its spinal implant products and surgical instruments to hospitals and medical facilities. The company’s revenue model is based on direct sales, as well as potential partnerships with distributors and medical institutions. Key revenue streams include the sale of various spinal implants, such as intervertebral cages, screws, and rods, as well as surgical instruments used in spinal procedures. Additionally, Spineway may benefit from ongoing relationships with healthcare providers, offering training and support services that can lead to repeat business and long-term contracts.

Spineway SA Financial Statement Overview

Summary

Spineway SA exhibits strong revenue growth, but profitability remains a significant challenge, with negative margins across the board. The balance sheet is stable with low leverage, yet the company struggles to generate returns on equity. Cash flow issues persist, with declining free cash flow and negative operating cash flow ratios, indicating potential liquidity concerns. Overall, while growth prospects are promising, the company needs to address profitability and cash flow management to improve its financial health.

Income Statement

Spineway SA has shown significant revenue growth with a 69.9% increase in the latest year, indicating strong top-line expansion. However, the company struggles with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin improved to 28.1%, but the net profit margin remains deeply negative at -32.3%, highlighting ongoing challenges in cost management and operational efficiency.

Balance Sheet

The balance sheet shows a low debt-to-equity ratio of 0.075, indicating conservative leverage and financial stability. However, the return on equity is negative at -15.9%, reflecting the company's inability to generate profits from its equity base. The equity ratio stands at a healthy level, suggesting a strong capital structure despite profitability issues.

Cash Flow

Cash flow analysis reveals a concerning decline in free cash flow, with a growth rate of -55%. The operating cash flow to net income ratio is negative, indicating cash flow challenges. However, the free cash flow to net income ratio is 1.0, suggesting that the company is managing to convert its net income into free cash flow effectively, despite overall negative cash flow figures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.15M	11.95M	10.52M	7.43M	4.29M	3.38M
Gross Profit	6.07M	3.36M	1.63M	237.00K	-1.45M	-2.12M
EBITDA	2.24M	-5.58M	-4.79M	-2.76M	-1.04M	-1.32M
Net Income	-1.89M	-3.86M	-6.51M	-3.14M	-1.58M	-14.05M
Balance Sheet
Total Assets	30.20M	30.41M	26.31M	27.70M	25.57M	14.75M
Cash, Cash Equivalents and Short-Term Investments	4.03M	4.52M	1.80M	5.50M	13.89M	4.86M
Total Debt	1.55M	1.82M	2.60M	1.43M	2.40M	2.89M
Total Liabilities	6.34M	6.17M	7.26M	5.69M	4.69M	4.73M
Stockholders Equity	23.86M	24.24M	19.05M	22.00M	20.88M	10.02M
Cash Flow
Free Cash Flow	580.00K	-3.27M	-7.29M	-13.89M	-2.88M	-1.39M
Operating Cash Flow	580.00K	-3.27M	-5.83M	-1.62M	-1.79M	-408.00K
Investing Cash Flow	-1.41M	-1.01M	-1.39M	-10.20M	-578.00K	-979.00K
Financing Cash Flow	3.23M	7.01M	3.49M	3.72M	11.45M	3.67M

Spineway SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALSPW, the sentiment is Negative. The current price of 0.19 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.17, and above the 200-day MA of 0.15, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.59 is Neutral, neither overbought nor oversold. The STOCH value of 29.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALSPW.

Spineway SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALSPW	48 Neutral	€5.46M	-2.41	-8.42%	―	-5.46%	99.75%